A joint report into the handling of the H1N1 outbreak has found that some scientists who advised governments to stockpile drugs, had previously been on the payroll of big drug companies.
The report, published in the British Medical Journal, found World Health Organisation (WHO) guidelines on the use of medicine to treat the virus were prepared by experts who had received consulting fees from the top two manufacturers of the drugs - Roche and GlaxoSmithKline.
The WHO's decision to name the flu a "pandemic" is also coming under scrutiny from European investigators, and stands accused of exaggerating the dangers of the H1N1 outbreak, which emerged in April last year.
Laboratory tests have confirmed more than 18,000 deaths from H1N1 infection, according to WHO figures, but the virus has turned out to be less deadly than feared.
Also, symptoms suffered by most people infected with the virus have been mild.
Report: WHO overstated H1N1 threat. Health body refusing to reveal details
A group of 14 law firms representing nearly 20,000 plaintiffs is seeking to intervene in Bayer’s...
As marijuana use among teens has grown in the past decade, researchers have been trying to...
The Food and Drug Administration Monday unveiled the details of a new policy designed to make...
